A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or Obesity
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
100actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-18 | actual | When the study began enrolling |
| Primary completion | 2025-07-26 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-26 | actual | The whole study's end, after follow-up |
| First posted | 2024-12-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Overweight
- Obesity
Interventions
- Drug: NNC0662-0419
- Other: Placebo (NNC0662-0419)
Primary outcomes
what the primary-completion date above is the date OFPart A: Number of treatment emergent adverse events (TEAE)
measured From timing of dosing on day 1 until completion of the end of study visit (up to 6 weeks)
Part B: Number of treatment-emergent adverse events (TEAE)
measured From timing of dosing on day 1 until completion of the end of study visit (up to 9 weeks)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed